Prediction Markets Criticized for Clinical Trial Bets

Kalshi and Polymarket now allow betting on clinical trial outcomes, drawing criticism from researchers and patients' families who warn of insider trading, tampering risks, and ethical harm. Critics call profiting from trial failures "ghastly," while platforms defend the practice as informative.